Shots:
- The companies sign a purchase agreement with Covax to supply 40M doses of the COVID-19 vaccine. First deliveries are expected in Q1’ 2021, subject to the execution of supply agreements under the Covax Facility structure
- Covax includes an Advanced Market Commitment (AMC) financial mechanism under which Pfizer and BioNTech will provide access COVID-19 vaccines at a not-for-profit price in 92 countries
- The Pfizer-BioNTech COVID-19 Vaccine has been authorized from EUA for active immunization to prevent COVID-19 in individuals 16 years of age and older
Click here to read full press release/ article | Ref: Businesswire | Image: Week
The post Pfizer and BioNTech Signs an Agreement with Covax for Advance Purchase of Vaccine to Help Combat COVID-19 first appeared on PharmaShots.